Gilead Beats Expectations, Boosts Sales Outlook

Gilead Sciences exceeded Wall Street expectations with a $2.03 adjusted earnings per share, surpassing the forecast of $1.91, and a 4% increase in sales to $6.96 billion. Despite raising their 2026 sales outlook, they lowered their profit view to a loss of $1.00 to $0.65 per share due to recent acquisitions. Their HIV prevention drug Yezugo, launched last year, saw first quarter sales of $166 million, crushing the estimate of $143 million, with a projected $1 billion for 2026, up from $800 million. Investors are watching the mix of strong performers and some dips, with Biktarvy growing 7% to $3.36 billion, liver disease sales edging up 1% to $767 million, cell therapies dropping 12% from competition, but cancer fighter Trodelvy surging 37% to $402 million. The profit hit is due to an $11.5 billion charge in the next quarter for acquiring Arcellx, Ouro Medicines, and Tubulis. Gileads CEO expressed confidence in their expansion push despite this acquisition bump in the road. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/20df036eb73aeaf4